drugset / Trial / NCT02971696
Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of the study is to evaluate the efficacy of sorafenib, compared to the best supportive care (BSC), in two cohorts of patients who presented with advanced hepatocellular carcinoma (HCC) based on etiology of hepatitis C virus.
Timeline
- Start
- 2016-12
- Primary completion
- 2017-11
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | — |